• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of a novel treatment for IBD by inhibition of topical JAK signaling in the intestin.

Research Project

Project/Area Number 23K07413
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 53010:Gastroenterology-related
Research InstitutionTokyo Medical and Dental University

Principal Investigator

藤井 俊光  東京医科歯科大学, 大学院医歯学総合研究科, 寄附講座准教授 (30547451)

Co-Investigator(Kenkyū-buntansha) 永石 宇司  東京医科歯科大学, 大学院医歯学総合研究科, 寄附講座准教授 (60447464)
Project Period (FY) 2023-04-01 – 2026-03-31
Project Status Granted (Fiscal Year 2023)
Budget Amount *help
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2025: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2024: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2023: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Keywords炎症性腸疾患 / JAKシグナル / Drug Delivery System
Outline of Research at the Start

JAK阻害薬はIBDにおいて高い寛解導入率を示し難治例である生物学的製剤不応例においても有効性が認められているものの、感染症や血栓症など全身性の合併症が問題となり安易な導入は回避すべき位置づけとなっている。我々はこのJAK阻害薬を腸管局所へ直接デリバリーさせる坐剤や注腸製剤といった経直腸投与の局所製剤を開発し、薬剤の全身への曝露を回避することで合併症リスクを低減させつつ、直腸を含めた遠位大腸の炎症の鎮静化、それによる臨床的寛解、QOLの改善、粘膜治癒の達成による発癌抑制、長期予後改善をめざす。

Outline of Annual Research Achievements

JAK阻害薬はIBDにおいて高い寛解導入率を示し、生物学的製剤の不応例にも有効性が認められているにもかかわらず、感染症や血栓症など全身性の合併症が問題となり安易な導入は回避すべき位置づけとなっている。本研究で我々はこのJAK阻害薬を腸管局所へ直接デリバリーさせる坐剤や注腸製剤といった経直腸投与の局所製剤を開発することで、薬剤の全身への曝露を回避し合併症リスクを低減させつつ、直腸を含めた遠位大腸の炎症の鎮静化、それによる臨床的寛解、QOLの改善、粘膜治癒の達成による発癌抑制、また長期予後の改善をめざしている。そして当該期間に実施した研究結果から、以下のような成果が得られた。
1)JAK阻害薬の原末から、試験的な注腸剤を独自に調整することに成功した。2)次に正常マウスにおける毒性試験を行うにあたり、1回投与量や投与期間に関して多岐に亘るプロトコールを作成し、適切と思われるいくつかの条件を見出すことができた。3)そしてこれらのプロトコールを用いて野生型C57BL/6マウスにJAK阻害薬を注腸投与し、網羅的な病理学的解析を行った結果、血栓症や日和見感染、発癌性など想定された副反応を一切誘発しない最適な条件を見出すことに成功した。
これらの研究成果は、全身投与で想定されるようなJAK阻害薬の毒性は、その経直腸投与によって回避することが可能であることを示唆している。さらに現在、我々が見出した上記プロトコールに対して、より客観性を備えたデータを集積する目的で、single cell RNA seqによる網羅的解析を導入する準備を行っている。また、このプロトコールを用いたマウスIBDモデルにおける安全性試験や有効性試験の準備に着手しつつある。

Current Status of Research Progress
Current Status of Research Progress

2: Research has progressed on the whole more than it was originally planned.

Reason

IBDの病態に対しJAK阻害剤は有効性が確認されている一方、その重篤な副反応が大きな課題であり、Drug Delivery Systemの工夫によって難治例に対する安全で有効な新規治療薬が開発できる可能性に着目しているが、今回我々は独自のJAK阻害注腸剤を調整し、その適切な投与条件を見出し、そして想定された副反応を全て回避できる条件を確立できたことは大きな成果であるといえる。

Strategy for Future Research Activity

次年度は我々が独自に調整したJAK阻害注腸剤とその投与プロトコールを用いて、これによる副反応の有無をさらに詳細に解析するために、single cell RNA seqによる網羅的解析を導入し各臓器・各細胞腫に与える影響を解析する予定である。また同プロトコールの安全性や有効性を客観的に評価するために、動物IBDモデルを誘発しその臨床および病理学的解析、フローサイトメトリー、サイトカイン測定、また免疫組織染色などを行う予定である。

Report

(1 results)
  • 2023 Research-status Report
  • Research Products

    (48 results)

All 2024 2023 2022

All Journal Article (17 results) (of which Int'l Joint Research: 3 results,  Peer Reviewed: 12 results,  Open Access: 4 results) Presentation (31 results) (of which Int'l Joint Research: 20 results)

  • [Journal Article] Single cell analysis revealed that two distinct, unique CD4+ T cell subsets were increased in the small intestinal intraepithelial lymphocytes of aged mice.2024

    • Author(s)
      Yuki Yonemoto, Yasuhiro Nemoto, Ryo Morikawa, Nana Shibayama, Shigeru Oshima, Takashi Nagaishi, Tomohiro Mizutani, Go Ito, Satoru Fujii, Ryuichi Okamoto.
    • Journal Title

      Frontiers in Immunology.

      Volume: 15 Pages: 1340048-1340048

    • DOI

      10.3389/fimmu.2024.1340048

    • Related Report
      2023 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Combination of leucine-rich alpha-2 glycoprotein and fecal markers detect Crohn’s disease activity confirmed by balloon-assisted enteroscopy2024

    • Author(s)
      Kawamoto Ami、Takenaka Kento、Hibiya Shuji、Kitazume Yoshio、Shimizu Hiromichi、Fujii Toshimitsu、Saito Eiko、Ohtsuka Kazuo、Okamoto Ryuichi
    • Journal Title

      Intestinal Research

      Volume: 22 Issue: 1 Pages: 65-74

    • DOI

      10.5217/ir.2023.00092

    • Related Report
      2023 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] IgA による腸内細菌叢調節と腸管粘膜防御の検証.2023

    • Author(s)
      永石宇司.
    • Journal Title

      東京医科歯科大学医科同窓会会報.

      Volume: 301 Pages: 23-23

    • Related Report
      2023 Research-status Report
  • [Journal Article] 炎症性腸疾患モデルにおける炎症性発癌機構の解析.2023

    • Author(s)
      井上忠彦, 永石宇司.
    • Journal Title

      細胞.

      Volume: 55 Pages: 1005-1009

    • Related Report
      2023 Research-status Report
  • [Journal Article] IgAによる回腸免疫恒常性の維持.2023

    • Author(s)
      永石宇司, 井上忠彦, 伏見萌音, 山田大貴, 岡本隆一, 安達貴弘.
    • Journal Title

      消化器病学サイエンス.

      Volume: 7 Pages: 86-89

    • Related Report
      2023 Research-status Report
  • [Journal Article] 慢性下痢の原因となる薬剤.2023

    • Author(s)
      山田大貴, 永石宇司.
    • Journal Title

      IBD Research.

      Volume: 17 Pages: 112-115

    • Related Report
      2023 Research-status Report
  • [Journal Article] A case of venous stasis colitis possibly caused by eplerenone2023

    • Author(s)
      Eiko Saito, Kazuo Ohtsuka, Ami Kawamoto, Toshimitsu Fujii, Kento Takenaka, Shuji Hibiya, Hiromichi Shimizu, Masakazu Nagahori, Shohei Tomii, Ryuichi Okamoto
    • Journal Title

      Clin J Gastroenterol.

      Volume: 16 Issue: 1 Pages: 69-72

    • DOI

      10.1007/s12328-022-01722-5

    • Related Report
      2023 Research-status Report
    • Peer Reviewed
  • [Journal Article] Association of Ulcerative Colitis Symptom Severity and Proctocolectomy with Multidimensional Patient-Reported Outcomes: A Cross-Sectional Study.2023

    • Author(s)
      K. Matsuoka, H. Yamazaki, M. Nagahori, T. Kobayashi, T. Omori, Y. Mikami, T. Fujii, S. Shinzaki, M. Saruta, M. Matsuura, T. Yamamoto, S. Motoya, T. Hibi, M. Watanabe, J. Fernandez, S. Fukuhara, T. Hisamatsu.
    • Journal Title

      J Gastroenterol.

      Volume: 58 Issue: 8 Pages: 751-765

    • DOI

      10.1007/s00535-023-02005-7

    • Related Report
      2023 Research-status Report
    • Peer Reviewed
  • [Journal Article] Diagnosis and Clinical Features of Perianal Lesions in Newly Diagnosed Crohn’s Disease: Subgroup Analysis from Inception Cohort Registry Study of Patients with Crohn’s Disease (iCREST-CD)2023

    • Author(s)
      Yamamoto Takayuki、Nakase Hiroshi、Watanabe Kenji、et al
    • Journal Title

      Journal of Crohn's and Colitis

      Volume: Online ahead of print Issue: 8 Pages: 1-2

    • DOI

      10.1093/ecco-jcc/jjad038

    • Related Report
      2023 Research-status Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies2023

    • Author(s)
      Gao Xiang、Fujii Toshimitsu、Ye Byong Duk、Chou Jen‐Wei、Sugimoto Ken、Cao Qian、Kligys Kristina、Murakoshi Kaoru、Teng Dennis、Zhang Yafei、Nakase Hiroshi
    • Journal Title

      Journal of Gastroenterology and Hepatology

      Volume: 39 Issue: 1 Pages: 55-65

    • DOI

      10.1111/jgh.16358

    • Related Report
      2023 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] aintenance Risankizumab Sustains Induction Response in Patients with Crohn’s Disease in a Randomized Phase 3 Trial2023

    • Author(s)
      Ferrante M, Irving P M, Abreu M T, Axler J, Gao X, Cao Q, Fujii T, Rausch A, Torres J, Neimark E, Song A, Wallace K, Kligys K, Berg S, Liao X, Zhou Q, Kalabic J, Feagan B, Panaccione R
    • Journal Title

      J Crohns Colitis

      Volume: Online ahead of print Issue: 3 Pages: 416-423

    • DOI

      10.1093/ecco-jcc/jjad168

    • Related Report
      2023 Research-status Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] COVID-19 severity is associated with the risk of gastrointestinal bleeding2023

    • Author(s)
      Shuji Hibiya, Takashi Fujii, Toshimitsu Fujii, Shinji Suzuki, Mayumi Kondo, Shinya Ooka, Y Furumoto, S Azuma, K Tanaka, H Kurata, S Tanaka, M Kurosaki, K Nagayama, F Kusano, Y Iizuka, T Kawamura, H Ikemiyagi, S Sakita,T Yauchi, H Watanabe, A Kawamoto, Y Matsuyama, K Ohtsuka, R Okamoto
    • Journal Title

      BMJ Open Gastroenterol

      Volume: 10 Issue: 1 Pages: e001199-e001199

    • DOI

      10.1136/bmjgast-2023-001199

    • Related Report
      2023 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] 【炎症性腸疾患に対する検査法の進歩】Cross-sectional imagingとしてのMRIとtransmural healing2023

    • Author(s)
      1.藤井 俊光, 岡本 隆一
    • Journal Title

      日本消化器病学会雑誌

      Volume: 120 Pages: 888-897

    • Related Report
      2023 Research-status Report
    • Peer Reviewed
  • [Journal Article] 【小腸画像診断のトピックス】MR enterography2023

    • Author(s)
      2.竹中 健人, 藤井 俊光, 大塚 和朗, 岡本 隆一
    • Journal Title

      胃と腸

      Volume: 58 Pages: 1491-1498

    • Related Report
      2023 Research-status Report
    • Peer Reviewed
  • [Journal Article] 【潰瘍性大腸炎に対する同種同効薬を使い分ける!】JAK阻害薬はすべて同じ使い方か?2023

    • Author(s)
      3.藤井 俊光
    • Journal Title

      IBD Research

      Volume: 17 Pages: 267-274

    • Related Report
      2023 Research-status Report
  • [Journal Article] Transmural remission characterized by high biologic concentrations demonstrates better prognosis in Crohn's disease2022

    • Author(s)
      Kento Takenaka, Ami Kawamoto, Yoshio Kitazume, Toshimitsu Fujii, Yumi Udagawa, Hiromichi Shimizu, Shuji Hibiya, Masakazu Nagahori, Kazuo Ohtsuka, Mamoru Watanabe, Ryuichi Okamoto
    • Journal Title

      J Crohns Colitis.

      Volume: - Issue: 6 Pages: 855-862

    • DOI

      10.1093/ecco-jcc/jjac185

    • Related Report
      2023 Research-status Report
    • Peer Reviewed
  • [Journal Article] Serum Leucine-Rich α2 Glycoprotein: A Novel Biomarker for Transmural Inflammation in Crohn's Disease2022

    • Author(s)
      Kento Takenaka, Yoshio Kitazume, Ami Kawamoto, Toshimitsu Fujii, Yumi Udagawa, Ryosuke Wanatabe, Hiromichi Shimizu, Shuji Hibiya, Masakazu Nagahori, Kazuo Ohtsuka, Hiroyuki Sato, Akihiro Hirakawa, Mamoru Watanabe, Ryuichi Okamoto
    • Journal Title

      Am J Gastroenterol.

      Volume: - Issue: 6 Pages: 1028-1035

    • DOI

      10.14309/ajg.0000000000002127

    • Related Report
      2023 Research-status Report
    • Peer Reviewed
  • [Presentation] A pathogenic role of activated mucosal-associated invariant T cells in an animal model of Inflammatory Bowel Disease.2024

    • Author(s)
      Yusuke Yasutomi, Asako Chiba, Keiichi Haga, Goh Murayama, Ayako Makiyama, Akihito Nagahara, Takashi Nagaishi, Sachiko Miyake.
    • Organizer
      Annual meeting of European Crohn's and Colitis Organisation 2024.
    • Related Report
      2023 Research-status Report
    • Int'l Joint Research
  • [Presentation] Downregulated apelin expression in T cells in the setting of chronic colitis.2024

    • Author(s)
      Tadahiko Inoue, Mone Fushimi, Daiki Yamada, Taro Watabe, Mamoru Watanabe, Ryuichi Okamoto, Takashi Nagaishi.
    • Organizer
      Annual meeting of European Crohn's and Colitis Organisation 2024.
    • Related Report
      2023 Research-status Report
    • Int'l Joint Research
  • [Presentation] B cell receptor signaling-mediated activation in lymphoid tissues is regulated by the long isoform of CEACAM1.2024

    • Author(s)
      Tadahiko Inoue, Mone Fushimi, Naoya Tsugawa, Daiki Yamada, Taro Watabe, Mamoru Watanabe, Ryuichi Okamoto, Takahiro Adachi, Richard S. Blumberg, Takashi Nagaishi.
    • Organizer
      Annual meeting of Japanese Society of Immunology 2024.
    • Related Report
      2023 Research-status Report
    • Int'l Joint Research
  • [Presentation] APL downregulation in T cells in an animal model of chronic colitis.2024

    • Author(s)
      Mone Fushimi, Tadahiko Inoue, Daiki Yamada, Taro Watabe, Mamoru Watanabe, Ryuichi Okamoto, Takashi Nagaishi.
    • Organizer
      Annual meeting of Japanese Society of Immunology 2024.
    • Related Report
      2023 Research-status Report
    • Int'l Joint Research
  • [Presentation] 難治性潰瘍性大腸炎におけるカロテグラストとbiologicsのdual therapy2024

    • Author(s)
      藤井 俊光, 日比谷 秀爾, 河本 亜美, 田村 皓子, 森川 亮, 小林 桜子, 清水 寛路, 齊藤 詠子, 竹中 健人, 大塚 和朗, 岡本 隆一
    • Organizer
      第20回日本消化管学会総会学術集会
    • Related Report
      2023 Research-status Report
  • [Presentation] Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a final report of effectiveness and safety data2024

    • Author(s)
      Katsuyoshi Matsuoka, Satoshi Motoya, Takayuki Yamamoto, Minoru Matsuura, Toshimitsu Fujii, Shinichiro Shinzaki, Yohei Mikami, Shoko Arai, Junichi Oshima, Yutaka Endo, Hirotoshi Yuasa, Masato Hoshi, Keiko Sato, Tadakazu Hisamatsu
    • Organizer
      19th Congress of ECCO
    • Related Report
      2023 Research-status Report
    • Int'l Joint Research
  • [Presentation] Clinical features and surgical necessity rate of fistulisingperianal disease in newly diagnosed patients with Crohn's disease: Interim analysis of inception cohort registry study of patients with Crohn's disease (iCREST-CD)2024

    • Author(s)
      N.Takatsu, T.Yamamoto, H.Nakase, S.Shinzaki, K.Watanabe, T.Fujii, R.Okamoto, K.Matsuoka, A.Yamada, R.Kunisaki, M.Matsuura, H.Shiga, S.Bamba, Y.Mikami, T.Shimoyama, S.Motoya, T.Torisu, T.Kobayashi, N.Ohmiya, M.Saruta, S.Yoshigoe, Y.Murata, T.Hisamatsu
    • Organizer
      19th Congress of ECCO
    • Related Report
      2023 Research-status Report
    • Int'l Joint Research
  • [Presentation] Ozanimod as a once-daily oral therapy for Japanese patients with ulcerative colitis: results from the induction period of a phase 2/3 study (J-True North)2024

    • Author(s)
      Katsuyoshi Matsuoka, Hiroshi Nakase, Toshimitsu Fujii, Tadakazu Hisamatsu, Yasuo Suzuki, Mamoru Watanabe, Yoko Uchikawa, Shoichiro Goto, Go Fujimoto, Changliang Zhang, Toshifumi Hibi
    • Organizer
      19th Congress of ECCO
    • Related Report
      2023 Research-status Report
    • Int'l Joint Research
  • [Presentation] APL downregulation in T cells in the setting of chronic colitis.2023

    • Author(s)
      Mone Fushimi, Tadahiko Inoue, Daiki Yamada, Taro Watabe, Mamoru Watanabe, Ryuichi Okamoto, Takashi Nagaishi.
    • Organizer
      United European Gastroenterology Week 2024.
    • Related Report
      2023 Research-status Report
    • Int'l Joint Research
  • [Presentation] 潰瘍性大腸炎におけるウパダシチニブ 30mg 及び 15mg 維持療法のベネフィット比較:第 III 相 U-ACHIEVE 試験2023

    • Author(s)
      藤井 俊光,佐藤 真弘,池田 公俊,仲瀬 裕志
    • Organizer
      第109回日本消化器病学会総会
    • Related Report
      2023 Research-status Report
  • [Presentation] Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn's disease treated with upadacitinib2023

    • Author(s)
      M.C. Dubinsky, G. D’Haens, O. Dewit, P. Juillerat, R. Panaccione, T. Fujii, A.P. Lacerda, E. Dubcenco, S. Anyanwu, C. Doshi, M. Mallick, A. Garrison, J. Liu, E.V. Loftus Jr
    • Organizer
      18th Congress of ECCO
    • Related Report
      2023 Research-status Report
    • Int'l Joint Research
  • [Presentation] Severe COVID-19 is associated with risk of lower gastrointestinal bleeding2023

    • Author(s)
      Shuij Hibiya, Takashi Fujii, Toshimitsu Fujii, Kazuo Ohtsuka, Ryuichi Okamoto
    • Organizer
      UEG Week 2023 欧州消化器病学会
    • Related Report
      2023 Research-status Report
    • Int'l Joint Research
  • [Presentation] COMBINING LEUCINE-RICH ALPHA-2 GLYCOPROTEIN AND FAECAL BIOMARKERS FOR ACCURATE MONITORING OF SMALL BOWEL ACTIVITY IN CROHN’S DISEASE2023

    • Author(s)
      A. Kawamoto, K. Takenaka, S. Hibiya, Y. Kitazume, K. Ito, H. Shimizu, T. Fujii, E. Saito, K. Ohtsuka, R. Okamoto
    • Organizer
      UEG Week 2023 欧州消化器病学会
    • Related Report
      2023 Research-status Report
    • Int'l Joint Research
  • [Presentation] DUAL THERAPY WITH CAROTEGRAST (AJM300: ORAL α4 INTEGRIN ANTAGONIST) AND BIOLOGICS FOR REFRACTORY ULCERATIVE COLITIS2023

    • Author(s)
      T. Fujii , S. Hibiya , H. Shimizu , A. Kawamoto , K. Takenaka , E. Saito , M. Nagahori , K. Ohtsuka , R. Okamoto
    • Organizer
      UEG Week 2023 欧州消化器病学会
    • Related Report
      2023 Research-status Report
    • Int'l Joint Research
  • [Presentation] Efficacy of Induction Upadacitinib Therapy in East Asian Patients With Moderately to Severely Active Crohn’s Disease2023

    • Author(s)
      Minhu Chen, Xiang Gao, Kenji Watanabe, Toshimitsu Fujii, Jae Hee Cheon, Shu-Chen Wei, Dennis Teng, Ana P Lacerda, Valencia P Remple, Hiroshi Nakase
    • Organizer
      UEG Week 2023 欧州消化器病学会
    • Related Report
      2023 Research-status Report
    • Int'l Joint Research
  • [Presentation] The Efficacy of Induction Treatment With Guselkumab in Patients with Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Induction Study Results at Week 12 by Prior Advanced Therapy History2023

    • Author(s)
      B. Bressler, L. Peyrin-Biroulet, J.R. Allegretti, K.G. Huang, M. Germinaro, N. Shipitofsky, Y. Miao, H. Zhang, M. Bortlik, T. Hlavaty, T. Fujii, B.G. Feagan, B.E. Sands, A. Dignass on behalf of the QUASAR Investigators
    • Organizer
      UEG Week 2023 欧州消化器病学会
    • Related Report
      2023 Research-status Report
    • Int'l Joint Research
  • [Presentation] Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinib2023

    • Author(s)
      Marla C. Dubinsky, Geert D’Haens, Olivier Dewit, Pascal Juillerat, Remo Panaccione, Toshimitsu Fujii, Ana P Lacerda, Elena Dubcenco, Samuel Anyanwu, Chirag Doshi, Madhuja Mallick, Andrew Garrison, John Liu, Lena Thin, Edward V Loftus Jr
    • Organizer
      AGW 2023
    • Related Report
      2023 Research-status Report
    • Int'l Joint Research
  • [Presentation] Corticosteroid Discontinuation and Clinical Outcomes in Patients With Moderately to Severely Active Crohn’s Disease Treated With Upadacitinib2023

    • Author(s)
      Marla C. Dubinsky, Geert D’Haens, Olivier Dewit, Pascal Juillerat, Remo Panaccione, Toshimitsu Fujii, Ana P. Lacerda, Elena Dubcenco, Samuel Anyanwu, Chirag Doshi, Madhuja Mallick, Andrew Garrison, John Liu, Edward V. Loftus Jr
    • Organizer
      DDW2023 米国消化器病学会
    • Related Report
      2023 Research-status Report
    • Int'l Joint Research
  • [Presentation] Patients with Moderate-to-Severe Crohn’s Disease with and without Prior Biologic Failure Demonstrate Improved Endoscopic Outcomes with Risankizumab: Results from Phase 3 Induction and Maintenance Trials2023

    • Author(s)
      Marc Ferrante, Qian Cao, Toshimitsu Fujii, Astrid Rausch, Ezequiel Neimark, Alexandra Song, Kori Wallace, Kristina Kligys, Qing Zhou, Jasmina Kalabic, Brian Feagan
    • Organizer
      DDW2023 米国消化器病学会
    • Related Report
      2023 Research-status Report
    • Int'l Joint Research
  • [Presentation] Corticosteroid-Sparing Effect of Upadacitinib in Patients With Moderately to Severely Active Crohn’s Disease2023

    • Author(s)
      Marla C. Dubinsky, Geert D’Haens, Olivier Dewit, Pascal Juillerat, Remo Panaccione, Toshimitsu Fujii, Ana P Lacerda, Elena Dubcenco, Samuel Anyanwu, Chirag Doshi, John Liu, Andrew Garrison, Edward V Loftus Jr
    • Organizer
      ACG 2023 - American College of Gastroenterology
    • Related Report
      2023 Research-status Report
    • Int'l Joint Research
  • [Presentation] The Efficacy of Induction Treatment With Guselkumab in Patients with Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Induction Study Results at Week 12 by Prior Advanced Therapy History2023

    • Author(s)
      B. Bressler, L. Peyrin-Biroulet, J.R. Allegretti, K.G. Huang, M. Germinaro, N. Shipitofsky, Y. Miao, H. Zhang, M. Bortlik, T. Hlavaty, T. Fujii, B.G. Feagan, B.E. Sands, A. Dignass on behalf of the QUASAR Investigators
    • Organizer
      ACG 2023 - American College of Gastroenterology
    • Related Report
      2023 Research-status Report
    • Int'l Joint Research
  • [Presentation] Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinib2023

    • Author(s)
      Marla C. Dubinsky, Geert D’Haens, Olivier Dewit, Pascal Juillerat, Remo Panaccione, Toshimitsu Fujii, Ana P Lacerda, Elena Dubcenco, Samuel Anyanwu, Chirag Doshi, Madhuja Mallick, Andrew Garrison, John Liu, Edward V Loftus Jr
    • Organizer
      SGG Swiss congress 2023
    • Related Report
      2023 Research-status Report
    • Int'l Joint Research
  • [Presentation] 難治性潰瘍性大腸炎に対するcarotegrastおよびbiologicsのdual therapyの検討2023

    • Author(s)
      藤井俊光、青沼優子、清水寛路、日比谷秀爾、河本亜美、齊藤詠子、竹中健人、長堀正和、大塚和朗、岡本隆一
    • Organizer
      JDDW2023 日本消化器関連学会週間
    • Related Report
      2023 Research-status Report
  • [Presentation] クローン病患者における過去に無効であった生物学的製剤数別のリサンキズマブの有効性2023

    • Author(s)
      藤井 俊光、佐藤 真弘、大野 浩太、久松 理一
    • Organizer
      JDDW2023 日本消化器関連学会週間
    • Related Report
      2023 Research-status Report
  • [Presentation] 炎症性腸疾患における両立支援の実際と課題2023

    • Author(s)
      藤井俊光
    • Organizer
      JDDW2023 日本消化器関連学会週間
    • Related Report
      2023 Research-status Report
  • [Presentation] 経口α4インテグリン阻害剤のポジショニングと期待2023

    • Author(s)
      藤井俊光
    • Organizer
      JDDW2023 日本消化器関連学会週間
    • Related Report
      2023 Research-status Report
  • [Presentation] クローン病肛門病変の生物学的製剤に対する内視鏡評価2023

    • Author(s)
      竹中健人、河本亜美、藤井俊光、日比谷秀爾、田村皓子、森川亮、小林桜子、清水寛路、齊藤詠子、長堀正和、大塚和朗、岡本隆一
    • Organizer
      第14回日本炎症性腸疾患学会学術集会
    • Related Report
      2023 Research-status Report
  • [Presentation] 潰瘍性大腸炎に対するカロテグラストのリアルワールドとbiologicsとのdual therapy2023

    • Author(s)
      藤井俊光、日比谷秀爾、河本亜美、田村皓子、森川亮、小林桜子、清水寛路、齊藤詠子、竹中健人、大塚和朗、岡本隆一
    • Organizer
      第14回日本炎症性腸疾患学会学術集会
    • Related Report
      2023 Research-status Report
  • [Presentation] 難治性潰瘍性大腸炎におけるupadacitinib投与に伴う尋常性ざ瘡の解析2023

    • Author(s)
      藤井俊光、田村皓子、河本亜美、森川亮、小林桜子、日比谷秀爾、清水寛路、齊藤詠子、竹中健人、大塚和朗、岡本隆一
    • Organizer
      第14回日本炎症性腸疾患学会学術集会
    • Related Report
      2023 Research-status Report
  • [Presentation] ウパダシチニブを投与した中等症から重症の活動性クローン病患者での副腎皮質ステロイドの中止と転帰2023

    • Author(s)
      藤井 俊光、幡井 裕乙、新山 勇人、仲瀬 裕志
    • Organizer
      第14回日本炎症性腸疾患学会学術集会
    • Related Report
      2023 Research-status Report
  • [Presentation] IBD Advanced Therapyのstudyを紐解く2023

    • Author(s)
      藤井俊光
    • Organizer
      第14回日本炎症性腸疾患学会学術集会
    • Related Report
      2023 Research-status Report

URL: 

Published: 2023-04-13   Modified: 2024-12-25  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi